RCUS
Arcus Biosciences, Inc.
RCUS lost money over the past year, so it has no meaningful PE right now.
RCUS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
RCUS's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
RCUS PE Valuation
RCUS has no meaningful PE right now: it lost money over the past year.
RCUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RCUS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
RCUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.62 | -$0.18 |
| Q2 2026 | -$3.89 | -$0.72 |
| Q1 2026 | -$3.17 | +$1.02 |
| Q4 2025 | -$3.29 | -$0.19 |
| Q3 2025 | -$3.44 | -$0.29 |
| Q2 2025 | -$3.17 | -$0.08 |
| Q1 2025 | -$4.19 | -$1.08 |
| Q4 2024 | -$3.10 | +$1.05 |
RCUS lost $3.62 per share over the past year, about the same as its loss the year before.
RCUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9M | -65% |
| Q2 2026 | $41M | -74% |
| Q1 2026 | $17M | -39% |
| Q4 2025 | $33M | +27% |
| Q3 2025 | $26M | -46% |
| Q2 2025 | $160M | +310% |
| Q1 2025 | $28M | -81% |
| Q4 2024 | $26M | -16% |
RCUS's revenue has slid since its 2021 peak: $9M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1456% | -909 points |
| Q2 2026 | -234% | -229 points |
| Q1 2026 | -788% | -353 points |
| Q4 2025 | -345% | +51 points |
| Q3 2025 | -546% | -327 points |
| Q2 2025 | -5% | +267 points |
| Q1 2025 | -436% | -425 points |
| Q4 2024 | -396% | -103 points |
RCUS's operating margin was −1456% last quarter, down 909 points from the same quarter a year ago, near the bottom of its range since 2019.
RCUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | +$9M |
| Q2 2026 | -$119M | +$14M |
| Q1 2026 | -$138M | -$5M |
| Q4 2025 | -$121M | -$20M |
| Q3 2025 | -$97M | -488% |
| Q2 2025 | -$133M | -$39M |
| Q1 2025 | -$133M | -$127M |
| Q4 2024 | -$101M | -$7M |
RCUS has burned cash in almost every quarter: −$466M over the past year, against −$464M the year before.
RCUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1.3M shares |
| 1 year | +20% | +20.9M shares |
| 3 years | +71% | +52.8M shares |
| 5 years | +82% | +57.3M shares |
| Available history | +189% | +83.3M shares |
RCUS has 127M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
RCUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -2.7x | Net Cash |
| Q2 2022 | -3.8x | Net Cash |
| Q1 2022 | -8.5x | Net Cash |
| Q4 2021 | -2.6x | Net Cash |
RCUS has more cash than debt.
RCUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.2 | Neutral |
| Stochastic | 4.6 | Oversold |
RCUS's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
RCUS PE vs Healthcare Sector
| Metric | RCUS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RCUS has no meaningful PE right now: it lost money over the past year.
RCUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.1 | 16% below |
| 20 week MA | $25.5 | 30% below |
| 50 week MA | $23.9 | 26% below |
| 100 week MA | $18.0 | 1.1% below |
| 200 week MA | $17.8 | 0.1% above |
RCUS has fallen below most of its moving averages, though it's still 0.1% above its 200-week average.
RCUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $30.6 | +187% |
| 2021 | $30.6 | $44.6 | +46% |
| 2022 | $44.6 | $20.4 | -54% |
| 2023 | $20.4 | $19.1 | -6.4% |
| 2024 | $19.1 | $15.3 | -20% |
| 2025 | $15.3 | $23.1 | +51% |
| 2026 YTD | $23.1 | $17.8 | -23% |
RCUS's yearly returns have swung widely, from +187% in 2020 to −54% in 2022. It's down 23% so far in 2026.